<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-UG17L5AL</identifier><date>1998</date><creator>Anžič, Jožica</creator><creator>Benedik-Dolničar, Majda</creator><relation>documents/doc/U/URN_NBN_SI_doc-UG17L5AL_001.pdf</relation><relation>documents/doc/U/URN_NBN_SI_doc-UG17L5AL_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 40-49</format><identifier identifier_type="COBISSID_HOST">9181401</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-UG17L5AL</identifier><language>slv</language><publisher>Kancerološko združenje Slovenskega zdravniškega društva</publisher><publisher>Onkološki inštitut</publisher><publisher>Zveza slovenskih društev za boj proti raku</publisher><source>Onkološki vikend</source><rights>BY-NC-ND</rights><subject language_type_id="eng">Adverse effects</subject><subject language_type_id="eng">Antineoplastic agents</subject><subject language_type_id="eng">Child</subject><subject language_type_id="eng">Drug therapy</subject><subject language_type_id="eng">Neoplasms</subject><subject language_type_id="eng">Therapeutic use</subject><subject language_type_id="eng">Toxicity</subject><title>Zdravljenje s kemoterapijo</title></Record>